Pfizer CEO Ian Read said during the company’s quarterly call that there are ‘lots of ways’ to work with the new Trump administration, his comments coming on the same day several industry leaders met with the new US president.
Already scheduled to report Pfizer Inc.’s year-end financial results Jan. 31, CEO Ian Read missed the high-profile, face-to-face meeting with President Donald Trump that several other pharma and biotech CEOs attended. But he reassured investors there appear to be opportunities for the industry to work with the new president.
As far as whether or not Pfizer will review its pricing strategy, Read said no
Shares are hit as German conglomerate lowers revenue forecast.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.
